Cassava SciencesSAVA
About: Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
Employees: 30
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
26% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 35
6.89% more ownership
Funds ownership: 29.19% [Q3] → 36.08% (+6.89%) [Q4]
15% less funds holding
Funds holding: 160 [Q3] → 136 (-24) [Q4]
42% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 53
63% less call options, than puts
Call options by funds: $10.1M | Put options by funds: $27.2M
89% less capital invested
Capital invested by funds: $411M [Q3] → $45.1M (-$366M) [Q4]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Vernon Bernardino 14% 1-year accuracy 10 / 69 met price target | 49%upside $2 | Neutral Reiterated | 25 Mar 2025 |
Financial journalist opinion
Based on 6 articles about SAVA published over the past 30 days
